Radhika Tripuraneni
Director/Board Member chez TERNS PHARMACEUTICALS, INC.
Profil
Radhika Tripuraneni is an Independent Director at Terns Pharmaceuticals, Inc. She previously worked as Vice President-Medical Affairs at Alexion Pharmaceuticals, Inc., MyoKardia, Inc., and Synageva BioPharma Corp.
She also served as Chief Development Officer at Prothena Corp.
Plc.
Dr. Tripuraneni holds a graduate degree from Harvard University and undergraduate and doctorate degrees from the University of Missouri.
Postes actifs de Radhika Tripuraneni
| Sociétés | Poste | Début |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Director/Board Member | 26/07/2022 |
Anciens postes connus de Radhika Tripuraneni
| Sociétés | Poste | Fin |
|---|---|---|
| PROTHENA CORPORATION PLC | Corporate Officer/Principal | 01/09/2022 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 01/03/2018 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/01/2017 |
| ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2015 |
Formation de Radhika Tripuraneni
| Harvard University | Graduate Degree |
| University of Missouri | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROTHENA CORPORATION PLC | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
